MarketPulse

metabolic diseases

2 articles
The Motley FoolThe Motley Fool··Eric Trie

ORBIMED Advisors Reduces Terns Pharma Position Despite 858% Annual Gain

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.
LLYTERNEWvaluationbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aardvark Therapeutics Issues 152K Stock Options to New Hires

Aardvark Therapeutics granted 152,338 stock options to six new hires with exercise prices of $13.48-$12.67, vesting over four years with a one-year cliff.
AARDclinical-stagebiopharmaceutical